1. Home /
  2. Pharmaceuticals

Pharmaceuticals

McKesson, Cardinal Health, AmerisourceBergen Propose Opioid Settlement: Report

McKesson, Cardinal Health, AmerisourceBergen Propose Opioid Settlement: Report

Three pharma distributors propose a $10 billion plan to a group of state attorneys general in opioid-abuse settlement.

A Timeline of Botox's History

A Timeline of Botox's History

A timeline of how Botox became one of the most popular medical beauty procedures.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Amgen Changes the Narrative With Cancer Drug Breakthrough

Amgen Changes the Narrative With Cancer Drug Breakthrough

Amgen built on the momentum at a recent conference on its Q2 earnings call as management highlighted recent positive developments for its KRAS inhibitor drug.

Simulations Plus Can't Go Up Forever, so It's Time to Book the Profits

Simulations Plus Can't Go Up Forever, so It's Time to Book the Profits

Parabolic moves can be alluring, but if you are long on SLP, consider how far it can fall from here.

3 Watch Items for the Market That Don't Involve the Fed or Brexit

3 Watch Items for the Market That Don't Involve the Fed or Brexit

The trio to keep an eye on are U.S.-China trade talks, business investment and political rhetoric.

Celgene Posts Strong Second-Quarter Earnings, Raises Guidance

Celgene Posts Strong Second-Quarter Earnings, Raises Guidance

Drugmaker Celgene reports second-quarter adjusted earnings and revenue that beat analysts' forecasts and raises its guidance through the remainder of the year amid strong sales of its cancer and other disease-fighting treatments.

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.

Anika Therapeutics Gets a Quant Upgrade to Buy, Adding to Its Technical Breakout

Anika Therapeutics Gets a Quant Upgrade to Buy, Adding to Its Technical Breakout

Let's check out the latest charts and indicators.

Pfizer Deal Might Be Good Treatment for Mylan

Pfizer Deal Might Be Good Treatment for Mylan

But this off-patent tie-up comes with some questions -- such as why are so many Mylan executives hanging on?